“[In our research] we looked at the National Health and Nutrition [Examination] Survey that goes around every year. It’s a bus and it goes all over the country and interviews and takes blood specimens and other specimens [from] about 5,000 people a year to determine if we could see the prevalence of hepatitis C virus infection in that cohort of people.
In the years between 2001 and 2012, people who tested positive for hepatitis C antibody [had] a follow-up interview over the telephone to determine if they were aware of their status before the bus came around and took their blood, and if they were aware of their status, what kind of medical treatment they sought.
Our findings, from comparing the years of 2001 to 2006 and 2007 to 2012 showed that in 2001 to 2006, about 50% of people were aware that they were infected with hepatitis C prior to examination by the National Health and Nutrition Survey. That increased to 59% from 2007 to 2012, which makes us hope that more people are aware of their infection status when it comes to hepatitis C.
CAMBRIDGE, Mass., Jan. 25, 2017 (GLOBE NEWSWIRE) — Daktari Diagnostics, a company focused on making “Anywhere. Care.™” a reality with its portable and ultrasensitive immunoassay-based CarePlatform™, today announced that it has reached a milestone in its global collaboration with Merck, known as MSD outside the United States and Canada, for the development of Daktari’s rapid point-of-care (POC) hepatitis C virus (HCV) core antigen confirmatory test system.
Daktari has successfully completed the design of the cartridge prototype suitable for commercial production, triggering a milestone payment of an undisclosed sum from Merck.
Daktari’s developmental HCV POC system is designed to provide quantitative determination of HCV viral load as a means to confirm diagnosis of an active HCV infection from samples of whole blood. It is based on a high-sensitivity measurement of the HCV core antigen and allows for a single-test approach, reducing the need for patients to undergo multiple diagnostic tests, especially in low access settings. The POC system consists of an automated instrument with an integrated reagent cartridge subsystem.
After some debate, a bill that could help mitigate some of the deadly side effects of Virginia’s raging opioid epidemic has made a step forward in the General Assembly.
The House Health, Welfare and Institutions Committee on Thursday referred to the House Appropriations Committee a bill that would legalize syringe-services programs in Virginia.
The bill — brought forward by Del. John M. O’Bannon, III, R-Henrico — would allow the Virginia Department of Health to provide clean equipment such as needles and syringes to injection drug users in areas throughout the state where the opioid epidemic is particularly strong.
A Brazilian study has shown that a medication currently used for Hepatitis C can help fight the Zika virus. According to the research, the antiviral Sofosbuvir inhibits virus replication. The group of Brazilian researchers has published their findings today, in the scientific journal Scientific Reports.
The study was conducted by scientists from Oswaldo Cruz Foundation and the Federal University of Rio de Janeiro.
According to Thiago Moreno, the head of the team, both the Zika and the Hepatitis C viruses have a common protein: RNA polymerase. Sofosbuvir inhibits the protein, preventing the Hepatitis C virus from replicating. “Indeed, we found that Sofosbuvir has the same effects with the Zika virus,” the researchers said.
For 20 years, I’ve been advocating for people living with hepatitis C. I was diagnosed with hep C (formerly known as non-A, non-B hepatitis) in the early days of George H.W. Bush’s presidency. Clinton was president during my first treatment; George W. Bush resided during my second treatment. Obama held the office when I was cured.
In those years, hepatitis C never attracted much attention. Obama did more than other presidents did, but I am comparing his work to nothing, which is what previous presidents did. Hep C doesn’t garner public outcry. It doesn’t tear at the hearts of people and policy makers like Zika-induced microencephalopathy in babies does. It’s easy to see the innocence in babies. Adults with hep C don’t get much sympathy.
I believe that society turns away from people with hep C because it makes giant assumptions: a) that people acquired hepatitis C from drugs, b) drug users deserve the consequences of drug use, c) treating drug users is a poor investment since they will just go out and get infected again, and d) that babies don’t get hep C. But all of these assumptions are myths. Let’s take a closer look.
The first report of the Pan American Health Organization (PAHO) on viral hepatitis reveals the enormous scale of this silent epidemic in the Americas, and advocates an organized response by the countries of the region to prevent, detect and treat those who need it.
“Hepatitis is a silent epidemic because people who have the infections do not have symptoms until there is damage to the liver, and because the burden of the disease has not been fully recognized. informing people about these diseases and ways to prevent them is crucial,” according to Massimo Ghidinelli, chief of the HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections unit at PAHO/WHO.
Two drug combinations from Gilead and AbbVie that could improve treatment of chronic hepatitis C have been granted accelerated review in the EU.
Gilead’s application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve a cure for chronic hepatitis C virus (HCV) patients who have failed other regimens.
The new directly-acting antivirals can now cure more than 90% of people with all hepatitis C virus (HCV) genotypes, but there is still room for better options for the most difficult-to-treat people.
AUSTIN – A local clinic is helping to give Hepatitis C patients a second chance through a new drug that helps cure the virus.
The drug is called, Harvoni, an antiviral agent patients can get from Community Care Health Center, the clinic is a partnered up with Central Health and the Seton Healthcare Family to provide low-income Travis County residents access. So far, the group has already cured more than 500 patients through their pilot program over the last three years.
“If we can get rid of the virus, they aren’t going to be passing it on,” said Physician Assistant Jordan Nicquette.